Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Completed · Phase 2
Conditions studied: Head and Neck Cancer, Precancerous Condition
In brief
RATIONALE: Monoclonal antibodies, such as cetuximab, can block abnormal cell growth in different ways. Some block the ability of abnormal cells to grow and spread. Others find abnormal cells and help kill them or carry cell-killing substances to them. PURPOSE: This randomized phase II trial is studying how well cetuximab works in treating patients with precancerous lesions of the upper aerodigestive tract.
Key facts
- Study ID
- NCT00524017
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 35
- Starts
- 2007-05-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2020-03-12
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Lucille P. Markey Cancer Center at University of Kentucky — Lexington, Kentucky, United States
- Greenebaum Cancer Center at University of Maryland Medical Center — Baltimore, Maryland, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- NYU Cancer Institute at New York University Medical Center — New York, New York, United States
- UPMC Cancer Centers — Pittsburgh, Pennsylvania, United States
- Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina, United States
- British Columbia Cancer Agency - Vancouver Cancer Centre — Vancouver, British Columbia, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.